Comparison study of oral iron preparations using a human intestinal model

Scientia Pharmaceutica

Volumn 81, Issue 4, 2013, Pages 1123-1139

  Zariwala, Mohammed Gulrez ^a   Somavarapu, Satyanarayana ^b   Farnaud, Sebastien ^c   Renshaw, Derek ^a  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

Author keywords

Anaemia; Caco 2; Dissolution; Ferritin; Iron supplements

Indexed keywords

ASCORBIC ACID; FERRITIN; FERROGLOBIN; FERROGRAD C; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FLORADIX; FOLIC ACID; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IRON ABSORPTION; IRON METABOLISM; IRON THERAPY; IRON TRANSPORT; PH;

EID: 84886720506     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1304-03     Document Type: Article

References (43)

1. Andrews NC. Disorders of Iron Metabolism. New Eng J Med. 1999; 341: 1986-1995. http://dx.doi.org/10.1056/NEJM199912233412607
2. Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem. 2002; 91: 9-18. http://dx.doi.org/10.1016/S0162-0134(02)00461-0
3. Miret S, Simpson RJ, McKie AT. Physiology and molecular biology of dietary iron absorption. Annu Rev Nutri. 2003; 23: 283-301. http://www.ncbi.nlm.nih.gov/pubmed/12626689
4. Muir A, Hopfer U. Regional specificity of iron uptake by small intestinal brush-border membranes from normal and iron-deficient mice. Am J Physiol. 1985; 248: G376-G379. http://www.ncbi.nlm.nih.gov/pubmed/3976894
5. Riedel HD, Remus AJ, Fitscher BA, Stremmel W. Characterization and partial purification of a ferrireductase from human duodenal microvillus membranes. Biochem J. 1995; 309: 745-748. http://www.ncbi.nlm.nih.gov/pubmed/7639688
6. Garrick MD, Garrick LM. Cellular iron transport. Biochim Biophys Acta. 2009; 1790: 309-325. http://dx.doi.org/10.1016/j.bbagen.2009.03.018
7. Laftah AH, Latunde-Dada GO, Fakih S, Hider RC, Simpson RJ, McKie AT. Haem and folate transport by proton-coupled folate transporter/haem carrier protein 1 (SLC46A1). Br J Nutr. 2009; 101: 1150-1156. http://dx.doi.org/10.1017/S0007114508066762
8. Conrad ME, Umbreit JN. A concise review: Iron absorption-the mucin-mobilferrin-integrin pathway. A competitive pathway for metal absorption. Am J Hematol. 1993; 42: 67-73. http://dx.doi.org/10.1002/ajh.2830420114
9. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet. 2007; 370: 511-520. http://dx.doi.org/10.1016/S0140-6736(07)61235-5
10. Iolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica 2009; 94: 395-408. http://dx.doi.org/10.3324/haematol.13619
11. Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr. 2001; 4: 537-545. http://dx.doi.org/10.1079/PHN2001139
12. Usha R, ed. Functional Consequences of Nutritional Anemia during Pregnancy and Early Childhood. In: Nutritional Anemias. CRC Press, Taylor & Francis Group, 2000: 43-68.
13. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243: 1726-1731. http://dx.doi.org/10.1001/jama.1980.03300430028018
14. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut. 2011; 60: 1309-1316. http://dx.doi.org/10.1136/gut.2010.228874
15. Fish WW. Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Methods Enzymol, 1988; 158: 357-364. http://dx.doi.org/10.1016/0076-6879(88)58067-9
16. Glahn RP, Gangloff MB, Van Campen DR, Miller DD, Wien EM, Norvell WA. Bathophenanthrolene disulfonic acid and sodium dithionite effectively remove surface-bound iron from Caco-2 cell monolayers. J Nutr. 1995; 125: 1833-1840. http://www.ncbi.nlm.nih.gov/pubmed/7616298
17. Dugdale M. Anemia. Obstet Gynecol Clin North Am. 2001; 28: 363-381. http://dx.doi.org/10.1016/S0889-8545(05)70206-0
18. Crosby WH. The rationale for treating iron deficiency anemia. Arch Intern Med. 1984; 144: 471-472. http://dx.doi.org/10.1001/archinte.1984.00350150055016
19. Saha L, Pandhi P, Gopalan S, Malhotra S, Saha PK. Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women. MedGenMed 2007; 9: 1. http://www.ncbi.nlm.nih.gov/pubmed/17435611
20. Schümann K, Ettle T, Szegner B, Elsenhans B, Solomons NW. On risks and benefits of iron supplementation recommendations for iron intake revisited. J Trace Elem Med Biol. 2007; 21: 147-168. http://dx.doi.org/10.1016/j.jtemb.2007.06.002
21. Fairweather-Tait S, Lynch S, Hotz C, Hurrell R, Abrahamse L, Beebe S, Bering S, Bukhave K, Glahn R, Hambidge M, Hunt J, Lonnerdal B, Miller D, Mohktar N, Nestel P, Reddy M, Sandber AS, Sharp P, Teucher B, Trinidad TP. The usefulness of in vitro models to predict the bioavailability of iron and zinc: a consensus statement from the HarvestPlus expert consultation. Int J Vitam Nutr Res. 2005; 75: 371-374. http://dx.doi.org/10.1024/0300-9831.75.6.371
22. Gangloff MB, Lai C, Van Campen DR, Miller DD, Norvell WA, Glahn RP. Ferrous iron uptake but not transfer is down-regulated in Caco-2 cells grown in high iron serum-free medium. J Nutr. 1996; 126: 3118-3127. http://www.ncbi.nlm.nih.gov/pubmed/9001382
23. Yun S, Habicht JP, Miller DD, Glahn RP. An in vitro digestion/Caco-2 cell culture system accurately predicts the effects of ascorbic acid and polyphenolic compounds on iron bioavailability in humans. J Nutr. 2004; 134: 2717-2721. http://www.ncbi.nlm.nih.gov/pubmed/15465772
24. Zhu L, Glahn RP, Yeung CK, Miller DD. Iron uptake by Caco-2 cells from NaFeEDTA and FeSO4: Effects of ascorbic acid, pH, and a Fe(II) chelating agent. J Agric Food Chem. 2006; 54: 7924-7928. http://dx.doi.org/10.1021/jf061036z
25. Perales S, Barberá R, Lagarda MJs, Farré R. Availability of iron from milk-based formulas and fruit juices containing milk and cereals estimated by in vitro methods (solubility, dialysability) and uptake and transport by Caco-2 cells. Food Chem. 2007; 102: 1296-1303. http://dx.doi.org/10.1016/j.foodchem.2006.07.019
26. Forbes AL, Arnaud MJ, Chichester CO, Cook JD, Harrison BN, Hurrell RF, Kahn SG, Morris ER, Tanner JT, Whittaker P, et al. Comparison of in vitro, animal, and clinical determinations of iron bioavailability: International Nutritional Anemia Consultative Group Task Force report on iron bioavailability. Am J Clin Nutr. 1989; 49: 225-238. http://www.ncbi.nlm.nih.gov/pubmed/2644802
27. Little DR. Ambulatory management of common forms of anemia. Am Fam Physician. 1999; 59: 1598-1604. http://www.ncbi.nlm.nih.gov/pubmed/10193599
28. Glahn RP, Wortley GM, South PK, Miller DD. Inhibition of iron uptake by phytic acid, tannic acid, and ZnCl2: studies using an in vitro digestion/Caco-2 cell model. J Agric Food Chem. 2002; 50: 390-395. http://dx.doi.org/10.1021/jf011046u
29. Hallberg L, Rossander L, Skanberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr. 1987; 45: 988-996. http://www.ncbi.nlm.nih.gov/pubmed/3034044
30. Hurrell RF, Reddy M, Cook JD. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br J Nutr. 1999; 81: 289-295. http://www.ncbi.nlm.nih.gov/pubmed/10999016
31. Kobayashi M, Sada N, Sugawara M, Iseki K, Miyazaki K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm 2001; 221: 87-94. http://dx.doi.org/10.1016/S0378-5173(01)00663-9
32. Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989; 17: 69-89. http://dx.doi.org/10.2165/00003088-198917020-00002
33. Joint Formulary Committee (2012). British National Formulary. 63rd edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
34. Raskin HF. Barium-burger roentgen study for unrecognized, clinically significant, gastric retention. South Med J. 1971; 64: 1227-1235. http://dx.doi.org/10.1097/00007611-197110000-00014
35. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician 2007; 75: 671-678. http://www.ncbi.nlm.nih.gov/pubmed/17375513
36. Bannerman J, Campbell NRC, Hasinoff BB, Venkataram S. The dissolution of iron from various commercial preparations. Pharm Acta Helv. 1996; 71: 129-133. http://dx.doi.org/10.1016/0031-6865(96)00002-7
37. Sharp P. Methods and options for estimating iron and zinc bioavailability using Caco-2 cell models: benefits and limitations. Int J Vitam Nutr Res. 2005; 75: 413-421. http://dx.doi.org/10.1024/0300-9831.75.6.413
38. Jackson K, Young D, Pant S. Drug/excipient interactions and their affect on absorption. Pharm Sci Technolo Today 2000; 3: 336-345. http://dx.doi.org/10.1016/S1461-5347(00)00301-1
39. Kim SK. Small intestine transit time in the normal small bowel study. Am J Roentgenol Radium Ther Nucl Med. 1968; 104: 522-524. http://dx.doi.org/10.2214/ajr.104.3.522
40. Walker SE, Paton TW, Cowan DH, Manuel MA, Dranitsaris G. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ 1989; 141: 543-547. http://www.ncbi.nlm.nih.gov/pubmed/2776093
41. Panakanti R, Narang AS. Impact of excipient interactions on drug bioavailability from solid dosage forms. Pharm Res. 2012; 29: 2639-2659. http://dx.doi.org/10.1007/s11095-012-0767-8
42. Singh P, Guillory JK, Sokoloski TD, Benet LZ, Bhatia VN. Effect of inert tablet ingredients on drug absorption. I. Effect of polyethylene glycol 4000 on the intestinal absorption of four barbiturates. J Pharm Sci. 1966; 55: 63-68. http://dx.doi.org/10.1002/jps.2600550114
43. Kaojarern S, Nathakarnkikool S, Suvanakoot U. Comparative bioavailability of praziquantel tablets. DICP. 1989; 23: 29-32. http://www.ncbi.nlm.nih.gov/pubmed/2718480